Intra Cellular Therapies Valuation
| ITCIDelisted Stock | USD 131.87 0.03 0.02% |
At this time, the firm appears to be overvalued. Intra Cellular Therapies retains a regular Real Value of $101.46 per share. The prevalent price of the firm is $131.87. Our model calculates the value of Intra Cellular Therapies from evaluating the firm fundamentals such as Return On Equity of -0.0858, current valuation of 13.06 B, and Return On Asset of -0.0696 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Intra Cellular's price fluctuation is very steady at this time. Calculation of the real value of Intra Cellular Therapies is based on 3 months time horizon. Increasing Intra Cellular's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Intra Cellular is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Intra Stock. However, Intra Cellular's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 131.87 | Real 101.46 | Hype 131.87 | Naive 134.87 |
The intrinsic value of Intra Cellular's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Intra Cellular's stock price.
Estimating the potential upside or downside of Intra Cellular Therapies helps investors to forecast how Intra stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Intra Cellular more accurately as focusing exclusively on Intra Cellular's fundamentals will not take into account other important factors: Intra Cellular Total Value Analysis
Intra Cellular Therapies is currently forecasted to have valuation of 13.06 B with market capitalization of 14.05 B, debt of 16.98 M, and cash on hands of 628.74 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Intra Cellular fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
13.06 B | 14.05 B | 16.98 M | 628.74 M |
Intra Cellular Investor Information
About 96.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.73. Intra Cellular Therapies had not issued any dividends in recent years. Based on the analysis of Intra Cellular's profitability, liquidity, and operating efficiency, Intra Cellular Therapies is not in a good financial situation at the moment. It has a very high risk of going through financial straits in August.Intra Cellular Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Intra Cellular has an asset utilization ratio of 49.81 percent. This signifies that the Company is making $0.5 for each dollar of assets. An increasing asset utilization means that Intra Cellular Therapies is more efficient with each dollar of assets it utilizes for everyday operations.Intra Cellular Ownership Allocation
Intra Cellular Therapies has a total of 106.52 Million outstanding shares. The majority of Intra Cellular Therapies outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Intra Cellular to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Intra Cellular Therapies. Please pay attention to any change in the institutional holdings of Intra Cellular Therapies as this could imply that something significant has changed or is about to change at the company. On May 14, 2025, Representative Josh Gottheimer of US Congress acquired under $15k worth of Intra Cellular Therapies's common stock.Intra Cellular Profitability Analysis
The company reported the previous year's revenue of 680.85 M. Net Loss for the year was (74.68 M) with profit before overhead, payroll, taxes, and interest of 387.77 M.About Intra Cellular Valuation
An absolute valuation paradigm, as applied to Intra Stock, attempts to find the value of Intra Cellular Therapies based on its fundamental and basic technical indicators. By analyzing Intra Cellular's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Intra Cellular's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Intra Cellular. We calculate exposure to Intra Cellular's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Intra Cellular's related companies.Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people.
Intra Cellular Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 103.1 M | |
| Forward Price Earnings | 158.7302 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Intra Stock
If you are still planning to invest in Intra Cellular Therapies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intra Cellular's history and understand the potential risks before investing.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |